Seminars in Nuclear Medicine
Volume 39, Issue 2 , Pages 115-123 , March 2009

Recent Trends in Soft-Tissue Infection Imaging

  • Nicholas Petruzzi, MD

      Affiliations

    • Department of Radiology, Thomas Jefferson University, Philadelphia, PA
    • ,
  • Nylla Shanthly, MBBS, DRM

      Affiliations

    • Department of Nuclear Medicine, Christian Medical College, Vellore, Tamilnadu, India
    • ,
  • Mathew Thakur, PhD

      Affiliations

    • Department of Radiology, Thomas Jefferson University, Philadelphia, PA
    • Corresponding Author InformationAddress reprint requests to Mathew L. Thakur, PhD, Department of Radiology, Thomas Jefferson University Hospital, 1020 Locust Street, Ste 359 JAH, Philadelphia, PA 19107

References 

  1. Rennen HJ, Boerman OC, Oyen WJ, et al. Imaging infection/inflammation in the new millennium. Eur J Nucl Med. 2001;28:241–252
  2. Boerman OC, Rennen H, Oyen WJ, et al. Radiopharmaceuticals to image infection and inflammation. Semin Nucl Med. 2001;31:286–295
  3. Tulchinsky M, Peters AM. Leukocyte receptor-binding radiopharmaceuticals for infection and inflammation scintigraphy. J Nucl Med. 2005;46:718–721
  4. Thakur ML, Lavender JP, Arnot RN, et al. Indium-111-labeled autologous leukocytes in man. J Nucl Med. 1977;18:1014–1021
  5. Vinjamuri S, Hall AV, Solanki KK, et al. Comparison of 99mTc infection imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection. Lancet. 1996;347:233–235
  6. van Eerd JE, Oyen WJ, Harris TD, et al. A bivalent leukotriene B(4) antagonist for scintigraphic imaging of infectious foci. J Nucl Med. 2003;44:1087–1091
  7. Fischman AJ, Babich JW, Strauss HW. A ticket to ride: Peptide radiopharmaceuticals. J Nucl Med. 1993;34:2253–2263
  8. Rennen HJ, Laverman P, van Eerd JE, et al. PET imaging of infection with a HYNIC-conjugated LTB4 antagonist labeled with F-18 via hydrazone formation. Nucl Med Biol. 2007;34:691–695
  9. Kjaer A, Lebech AM, Eigtved A, et al. Fever of unknown origin: Prospective comparison of diagnostic value of 18F-FDG PET and 111In-granulocyte scintigraphy. Eur J Nucl Med Mol Imaging. 2004;31:622–626
  10. Tsan MF. Mechanism of gallium-67 accumulation in inflammatory lesions. J Nucl Med. 1985;26:88–92
  11. McAfee JG, Thakur ML. Survey of radioactive agents for in vitro labeling of phagocytic leukocytes (II. particles). J Nucl Med. 1976;17:488–492
  12. Datz FL. Abdominal abscess detection: Gallium, 111In-, and 99mTc-labeled leukocytes, and polyclonal and monoclonal antibodies. Semin Nucl Med. 1996;26:51–64
  13. Fischman AJ, Fucello AJ, Pellegrino-Gensey JL, et al. Effect of carbohydrate modification on the localization of human polyclonal IgG at focal sites of bacterial infection. J Nucl Med. 1992;33:1378–1382
  14. Shepherd PR, Kahn BB. Glucose transporters and insulin action—implications for insulin resistance and diabetes mellitus. N Engl J Med. 1999;341:248–257
  15. Meller J, Altenvoerde G, Munzel U, et al. Fever of unknown origin: Prospective comparison of [18F]FDG imaging with a double-head coincidence camera and gallium-67 citrate SPET. Eur J Nucl Med. 2000;27:1617–1625
  16. Osman S, Danpure HJ. The use of 2-[18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography. Int J Rad Appl Instrum B. 1992;19:183–190
  17. Forstrom LA, Dunn WL, Mullan BP, et al. Biodistribution and dosimetry of [(18)F]fluorodeoxyglucose labelled leukocytes in normal human subjects. Nucl Med Commun. 2002;23:721–725
  18. Forstrom LA, Mullan BP, Hung JC, et al. 18F-FDG labelling of human leukocytes. Nucl Med Commun. 2000;21:691–694
  19. Dumarey N, Egrise D, Blocklet D, et al. Imaging infection with 18F-FDG-labeled leukocyte PET/CT: Initial experience in 21 patients. J Nucl Med. 2006;47:625–632
  20. Locher JT, Seybold K, Andres RY, et al. Imaging of inflammatory and infectious lesions after injection of radioiodinated monoclonal anti-granulocyte antibodies. Nucl Med Commun. 1986;7:659–670
  21. Thakur ML, Thiagarajan P, White F, et al. Monoclonal antibodies for specific cell labeling: Considerations, preparations and preliminary evaluation. Nucl Med. and Biol. 1987;14:51–58
  22. Mozley PD, Thakur ML, Alavi A, et al. Effects of a 99mTc-labeled murine immunoglobulin M antibody to CD15 antigens on human granulocyte membranes in healthy volunteers. J Nucl Med. 1999;40:2107–2114
  23. Chen DL, Ferkol TW, Mintun MA, et al. Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography. Am J Respir Crit Care Med. 2006;173:1363–1369
  24. Chen DL, Schuster DP. Imaging pulmonary inflammation with positron emission tomography: A biomarker for drug development. Mol Pharm. 2006;3:488–495
  25. Chen DL, Rosenbluth DB, Mintun MA, et al. FDG PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin. J Appl Physiol. 2006;100:1602–1609
  26. Buchler T, Bomanji J, Lee SM. FDG PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease–a useful tool for monitoring pulmonary toxicity and disease activity. Haematologica. 2007;92:e120–e121
  27. Jones HA, Sriskandan S, Peters AM, et al. Dissociation of neutrophil emigration and metabolic activity in lobar pneumonia and bronchiectasis. Eur Respir J. 1997;10:795–803
  28. Mahfouz T, Miceli MH, Saghafifar F, et al. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: A study of 165 infectious episodes. J Clin Oncol. 2005;23:7857–7863
  29. Annovazzi A, Bagni B, Burroni L, et al. Nuclear medicine imaging of inflammatory/infective disorders of the abdomen. Nucl Med Commun. 2005;26:657–664
  30. Calder JD, Gajraj H. Recent advances in the diagnosis and treatment of acute appendicitis. Br J Hosp Med. 1995;54:129–133
  31. Meller J, Sahlmann CO, Scheel AK. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med. 2007;48:35–45
  32. Stumpe KD, Dazzi H, Schaffner A, et al. Infection imaging using whole-body FDG PET. Eur J Nucl Med. 2000;27:822–832
  33. Bleeker-Rovers CP, de Kleijn EM, Corstens FH, et al. Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur J Nucl Med Mol Imaging. 2004;31:29–37
  34. Ingui CJ, Shah NP, Oates ME. Infection scintigraphy: Added value of single-photon emission computed tomography/computed tomography fusion compared with traditional analysis. J Comput Assist Tomogr. 2007;31:375–380
  35. Roach PJ, Schembri GP, Ho Shon IA, et al. SPECT/CT imaging using a spiral CT scanner for anatomical localization: Impact on diagnostic accuracy and reporter confidence in clinical practice. Nucl Med Commun. 2006;27:977–987
  36. Kataoka H, Inoue M, Shinkai T, et al. Early dynamic SPECT imaging in acute viral encephalitis. J Neuroimaging. 2007;17:304–310
  37. Kang K, Lim I, Roh JK. Positron emission tomographic findings in a tuberculous brain abscess. Ann Nucl Med. 2007;21:303–306
  38. Floeth FW, Pauleit D, Sabel M, et al. 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med. 2006;47:776–782
  39. Falagas ME, Valotassiou VJ, Papadouli D, et al. 99mTechnetium-ciprofloxacin scintigraphy for the evaluation of spinal infections: A preliminary report. Clin Orthop Relat Res. 2006;444:34–37
  40. Basu S, Alavi A. Role of FDG PET in the clinical management of paraneoplastic neurological syndrome: Detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol. 2008;10:131–137
  41. De Winter F, Gemmel F, Van Laere K, et al. 99mTc-ciprofloxacin planar and tomographic imaging for the diagnosis of infection in the postoperative spine: Experience in 48 patients. Eur J Nucl Med Mol Imaging. 2004;31:233–239
  42. Jones-Jackson L, Walker R, Purnell G, et al. Early detection of bone infection and differentiation from post-surgical inflammation using 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography (FDG PET) in an animal model. J Orthop Res. 2005;23:1484–1489
  43. Lin WY, Chao TH, Wang SJ. Clinical features and gallium scan in the detection of post-surgical infection in the elderly. Eur J Nucl Med Mol Imaging. 2002;29:371–375
  44. Brust D, Polis M, Davey R, et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: Impact of disease stage and therapy on pattern of nodal activation. AIDS. 2006;20:985–993
  45. Gungor T, Engel-Bicik I, Eich G, et al. Diagnostic and therapeutic impact of whole body positron emission tomography using fluorine-18-fluoro-2-deoxy-D-glucose in children with chronic granulomatous disease. Arch Dis Child. 2001;85:341–345
  46. Depas G, Decortis T, Francotte N, et al. F-18 FDG PET in infectious diseases in children. Clin Nucl Med. 2007;32:593–598
  47. Bleeker-Rovers CP, Rennen HJ, Boerman OC, et al. 99mTc-labeled interleukin 8 for the scintigraphic detection of infection and inflammation: First clinical evaluation. J Nucl Med. 2007;48:337–343
  48. McAfee JG, Subramanian G, Gagne G. Technique of leukocyte harvesting and labeling: Problems and perspectives. Semin Nucl Med. 1984;14:83–106
  49. Thakur ML. New radionuclides in the diagnosis of obscure infections. Conn Med. 1981;45:302–304
  50. van Eerd JE, Boerman OC, Corstens FH, et al. Radiolabeled chemotactic cytokines: New agents for scintigraphic imaging of infection and inflammation. Q J Nucl Med. 2003;47:246–255
  51. Edwards DS, Liu S, Ziegler MC, et al. RP463: A stabilized technetium-99m complex of a hydrazino nicotinamide derivatized chemotactic peptide for infection imaging. Bioconjug Chem. 1999;10:884–891

 Supported by NIH CA109231, C027175, EB001809, 1S10RR23709, and PA ME-03-184.

PII: S0001-2998(08)00122-0

doi: 10.1053/j.semnuclmed.2008.10.005

Seminars in Nuclear Medicine
Volume 39, Issue 2 , Pages 115-123 , March 2009

Article Tools

* Image Usage & Resolution